Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regenerative Medicine Sector ARMs Itself With New Advocacy Group

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies and researchers developing cell-based and tissue engineering therapies form a lobbying group to improve federal policies surrounding their efforts. The Alliance for Regenerative Medicine is ramping up to make itself heard in Washington.

You may also be interested in...



Stem Cell Therapies Walk A Risky Regulatory Road

As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.

Stem Cell Therapies Walk A Risky Regulatory Road

As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.

NIH, FDA Seeking Better Methods To Evaluate MedTech Innovations

A new collaboration between the National Institutes of Health and FDA will spur research into new tools and methodologies to evaluate the safety and efficacy of innovative medical products

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel